Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares for approximately $5.13 million at an average price of $539.99, reducing her direct ownership by 2.84% to 324,443 shares.
- United Therapeutics reported quarterly EPS of $7.27, exceeding analyst expectations of $6.86, while revenue of $783.3 million fell short of estimates and declined 1.9% year over year.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target above the recent trading level; institutional investors own approximately 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $539.99, for a total transaction of $5,129,905.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company's stock, valued at $175,195,975.57. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
United Therapeutics Trading Up 0.3%
NASDAQ:UTHR opened at $541.51 on Friday. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35. The firm has a market cap of $23.23 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 3.86 and a beta of 0.49. The company's 50-day moving average is $513.75 and its two-hundred day moving average is $540.45.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.41 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have commented on UTHR shares. Jefferies Financial Group reaffirmed a "buy" rating and issued a $728.00 target price on shares of United Therapeutics in a research note on Wednesday. Royal Bank Of Canada boosted their price target on United Therapeutics from $677.00 to $708.00 and gave the company an "outperform" rating in a report on Thursday, October 8th. The Goldman Sachs Group reissued a "sell" rating and set a $368.00 price target on shares of United Therapeutics in a research note on Thursday. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Finally, Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $642.69.
Get Our Latest Report on UTHR
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Davidson Capital Management Inc. increased its position in United Therapeutics by 2.7% during the third quarter. Davidson Capital Management Inc. now owns 11,252 shares of the biotechnology company's stock worth $6,097,000 after purchasing an additional 297 shares during the last quarter. Brindle & Bay Financial Advisors LLC purchased a new position in United Therapeutics during the third quarter worth approximately $234,000. Signal Advisors Wealth LLC raised its stake in United Therapeutics by 5.7% during the third quarter. Signal Advisors Wealth LLC now owns 1,950 shares of the biotechnology company's stock worth $1,057,000 after purchasing an additional 105 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $417,000. Finally, Marquette Asset Management LLC boosted its holdings in shares of United Therapeutics by 19.8% in the 3rd quarter. Marquette Asset Management LLC now owns 1,210 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 200 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
Key United Therapeutics News
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: United Therapeutics settled all six patent and antitrust disputes with Liquidia, reducing litigation uncertainty surrounding Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement also limits YUTREPIA’s label, particularly by excluding the pulmonary hypertension associated with interstitial lung disease indication, which may protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
- Positive Sentiment: The settlement calls for Liquidia to make approximately $380.7 million in payments, providing United Therapeutics with financial compensation for resolving the disputes. The deal also gives investors more visibility into the future competitive landscape. LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
- Positive Sentiment: Jefferies raised its price target for United Therapeutics to $728. Other analysts also remain constructive: the stock carries a “Moderate Buy” consensus rating and an average target of $627.31, above the recent trading level. UTHR Price Target Raised to $728 at Jefferies
- Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her ownership by 2.84%. The transaction was disclosed in an SEC filing, but the remaining stake is substantial and the sale alone does not establish a change in business outlook. United Therapeutics CEO Stock Sale SEC Filing
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
